Cordis said Tuesday that it has launched the Saber PTA dilatation catheter in Europe and will soon be following that with launches in the U.S. and Japan.

The device, which is intended for the treatment of patients with peripheral arterial disease, received FDA 510(k) clearance on June 27, Cordis spokeswoman Janet Graesser told Device Daily Bulletin.

According to Cordis, the Saber PTA dilatation catheter enables physicians to treat a wider range of PAD patients with a single balloon brand, and offers outstanding crossability and a broad offering of balloon sizes for the widely used .018” over-the-wire platform.

The device is designed to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of natural or synthetic arteriovenous dialysis fistulae. It is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature, Cordis said.

The company estimates that 27 million people in North America and Western Europe have PAD, which is caused when fatty substances collect and adhere to the linings of the arteries. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.